Search

everythinglearnresearchcommunity

for

Search:↓

Patients with alopecia areata prefer treatments that regrow scalp hair quickly over how often they need to take the medication.

Inhibiting class I HDACs helps maintain hair growth ability in skin cells.

Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.

Two new compounds were found to effectively reduce hair growth in mice.

The combination of mint and Aloe vera serum may help reduce hair loss from chemotherapy.

PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

The protein CTCF is essential for skin development, maintaining hair follicles, and preventing inflammation.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Unmodified fullerene C60 promotes hair growth and may help treat hair loss.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Nε-(carboxymethyl) lysine delays hair growth by blocking a key protein.

DKK proteins could help diagnose and treat various non-cancerous diseases.

Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.

The Walleye dermal sarcoma virus cyclin causes excessive skin cell growth in mice.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Increased ODC activity leads to skin tumors by recruiting stem cells, not by toxic byproducts.

Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.

Skin irritants can promote hair growth by affecting specific skin proteins.

Sonidegib is effective and safe for treating advanced basal cell carcinoma, but biopsies are needed to confirm tumor clearance.

Mirex seems to promote a unique group of skin cells different from those affected by another tumor promoter, TPA.

Injury boosts normal skin cell growth, reducing cancer cell advantage.

CD2 might be a new treatment target for patchy alopecia areata.

Topical immunotherapy with DPCP is most effective for certain alopecia areata types, with success linked to age and disease duration, and influenced by a gene polymorphism.

EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.

Normal cells outcompete and remove mutant cells in the pancreas with the help of the EphA2 receptor.

Blocking S100A8 can reduce chemotherapy-induced hair loss.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Akt2 and SGK3 are both important for normal hair growth and development.